drugset / Trial / NCT03570697

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697

Phase 3 Completed 164 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.

Timeline

Start
2018-11-19
Primary completion
2020-12-18
Completion
2021-01-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 420 mg Subcutaneous
Background Atorvastatin Small molecule